epidermis, the eye, and in epithelia of the nasal cavity, oropharynx, anus, vagina, and urinary tract. Cutaneous melanomas are much more prevalent than noncutaneous melanomas, which are comprised of ocular and mucosal sites.
The incidence of cutaneous melanoma is increasing at a greater rate than any other human cancer in the U. S., and the increase in mortality is second only to lung cancer. 1 Since 1973, the incidence rate has been rising 4% to 6% each year. In 1998, it is estimated that approximately 41,600 new cases will be diagnosed in the U. S. 2 It is estimated that there will be 7200 deaths due to melanoma in the U. S., or 1 death every hour and 13 minutes. Lifetime analysis reveals that approximately 1 in 75 persons born in the year 2000 will develop a cutaneous melanoma during his or her lifetime. 3 One of the major factors associated with this rise in the incidence of cutaneous melanomas is the increased exposure of individuals to ultraviolet radiation. Unlike cutaneous melanomas, the incidence of both ocular and mucosal melanomas is believed to have remained stable. 4, 5 The purpose of this article was to review the casemix characteristics, management, and outcomes of melanoma in the U. S. for the last decade. This report includes patients diagnosed with cutaneous, mucous membrane, and ocular melanomas as well as melanomas of unknown primary sites. To depict these patterns of treatment and survival, analyses were performed on the National Cancer Data Base (NCDB), a database of cancer registry information created by the American College of Surgeons' Commission on Cancer (COC) and the American Cancer Society in 1987. 6, 7 All acute care hospitals are invited to submit their cancer registry data on an annual basis. For the most current NCDB call for data, 1227 hospitals contributed 689,714 records, representing an estimated 57% of all newly diagnosed cancer patients in 1994. Unlike single-institution studies, the NCDB registry data are able to provide treatment and survival information on a very large number of patients from a broad range of community-based and academic hospitals. These cancer registry data are a direct reflection of the actual information that is being compiled on these patients; for this reason, the database at times contains a large percentage of cases with unknown variables (such as stage and grade) with no capacity to audit the information.
Although cancer registries are planning to collect records directly from physicians' offices in the year 2000, the data in this article were not collected using this protocol. Because certain early stage melanomas can be diagnosed and treated in physicians' offices, it is possible that the counts in this article represent an undersampling of these types of patients.
METHODS
Hospital-based cancer registries provide their data to the NCDB through a computerized format. 6 To ensure standardization, the data are coded at the hospital level according to the Data Acquisition Manual, 8 the third and fourth editions of the American Joint Committee on Cancer (AJCC) Manual for Staging of Cancer, 9, 10 and the second edition of the World Health Organization's International Classification of Disease for Oncology (ICD-O 2). 11 Cases to be included in this study were extracted from the data base according to histology (ICD-O 2 melanoma codes M872-M879), year of diagnosis (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) , the patient's having been diagnosed and/or treated at the reporting hospital, and the patients' having presented with a primary tumor (vs. recurrent disease). An algorithm based on selected patient and disease characteristics was employed to identify and eliminate duplicate cases in which more than one hospital submitted a record on the same patient (e.g., a patient who received surgery at one facility and radiation therapy at another).
AJCC staging, used to describe the extent of disease, was applied to melanomas of the skin. This staging system employs Breslow's depth of penetration and Clark's level of invasion, regional lymph node status, and the presence or absence of metastatic disease. (Breslow's depth and Clark's level were not available for separate analysis.) For selected analyses, stage was grouped into early (Stages 0 -II) and advanced (Stages III-IV). Melanomas involving the eyelid were grouped with cutaneous melanomas. Although melanoma of the eyelid has a separate staging system, it is equivalent to the staging system for cutaneous melanomas. Histologies were classified as per ICD-O 2 codes. The four main histologic groupings, representing cutaneous melanomas, were: nodular (M8721), lentigo maligna (M8742), superficial spreading (M8743), and acral lentiginous (M8744) melanomas. The remaining histologies were categorized as "other" (e.g., melanoma, not otherwise specified [NOS] , amelanotic, desmoplastic, or spindle cell). Ocular melanomas were lesions involving the conjunctiva and uvea. Uveal melanomas involved tumors arising in the iris, ciliary body, and choroid. AJCC staging was recorded for uveal melanomas. However, AJCC stage groupings for conjunctival melanomas currently are not recommended. Mucosal melanomas are mucous membrane lesions arising in the head and neck, female genital tract, anal/rectal, and urinary tract. There is no staging system for mucosal melanomas, but lymph node status was a data element collected by cancer registries and analyzed in this report. Melanomas presenting as isolated metastatic lesions from unknown primary sites (i.e., no documentation of arising from cutaneous, ocular, or mucosal primary melanomas) were coded as "unknown primary melanomas" (according to ICD-O 2). 11 The presentation of these unknown primary melanomas as regional (i.e., lymph node) or distant metastasis (i.e., nonlymph node) was determined from the General Summary Stage (according to the Data Acquisition Manual) 8 and the presence of lymph node disease.
In addition to tumor site, histology, and staging, data regarding patient characteristics including age, gender, race/ethnicity, and income also were collected. Patient income was based on the average family income of the patient's zip code of residence as per the U. S. Census. Income was grouped into low (Ͻ $20,000, which was approximately the lowest 10% of all NCDB cancer cases), high (Ն $47,000, which was approximately the highest 10% of all NCDB cancer cases), and a middle-income group ranging from $20,000 -46,999. 6 In this report, treatment represents the first course of cancer-directed therapy for the index disease. More detailed surgical information (e.g., margin width) and subsequent management of persistent or recurrent disease are not available.
All analyses were performed using SPSS software. 12 To determine changes across time, patient and disease characteristics and treatment were broken down by diagnostic year groupings (with 1985-1989 representing the earlier time period and 1990 -1994 the later time period). Case-mix and treatment variables were broken down further by patient and disease stratifications of interest, with chi-square statistics performed on selected cross-tabulations.
Outcome information was calculated on patients diagnosed in the earlier time period only to allow for sufficient follow-up. Annual survival rates, illustrated through 5 years using the life tables method, represent disease specific rates from the date of diagnosis to the endpoint (defined as death with cancer). Pairwise comparisons using the Wilcoxon statistic were performed on selected survival analyses to determine whether the stratifications had significantly different survival rates. For cutaneous melanoma, those variables with significantly different (P Ͻ 0.05) survival rates in the univariate analyses were entered into a Cox proportional hazards model of regression analysis to determine their independent influence on survival.
RESULTS

Disease Characteristics
The anatomic site of melanomas changed little across these two year groups (Table 1A) . The vast majority of melanomas originated in the skin (91.2% for all years), with the next highest percentage being ocular (5.3% for all years). Other melanoma sites included unknown primary melanomas and mucous membrane melanomas comprising 2.2% and 1.3% of all reported melanomas, respectively. Among the unknown primary melanomas, 43.0% presented with regional (i.e., lymph node) metastasis and 57.0% presented with distant metastasis. Among mucosal melanomas, the incidence of head and neck, female genital, anal/rectal, and urinary tract melanomas was 55.4%, 18.0%, 23.8%, and 2.8%, respectively.
The histologic and stage distributions for cutaneous melanomas are illustrated in Table 1B . A large variety of histologic classifications were recorded. Among these classifications, four represented the more traditional "phenotypic" characteristics that commonly are referred to in clinical practice, which include lentigo maligna, superficial spreading, nodular, and acral lentiginous melanomas. There was no difference in the incidence of these phenotypic categories between the two year groups. Among these four categories for all years (excluding histologies classified as "other"), the percentages of lentigo maligna, superficial spreading, nodular, and acral lentiginous melanomas were 21.4%, 57.6%, 18.9%, and 2.1%, respectively. Histologies included in the group labeled "other" comprised 53.4% of all the cutaneous melanoma cases. Of these "other" histologies, 92.5% were "melanoma, NOS" cases, with the remaining representing unique, descriptive histologic features.
A large percentage of cutaneous melanomas were diagnosed at a localized stage, with 85.7% being Stage 0 -II for all years (Table 1B) . Although this percentage changed little between 1985-1989 and 1990 -1994 , the proportion of early stage melanomas that were reported as noninvasive (Stage 0) increased from 11.4% in the earlier time period to 16.4% in the later time period. For all years, the percentage of patients presenting with localized invasive melanomas (Stage I and II) was 70.8%. Patients who presented with regional lymph node disease (Stage III) or metastatic disease (Stage IV) at the time of their diagnosis was 8.9% and 5.3%, respectively, for all years. There was an impressive decrease in the proportion of patients who were not staged, dropping from 42.0% in 1985-1989 to 17.6% in 1990 -1994 .
The stages at presentation for the different histologies of cutaneous melanoma (all years combined) are summarized in Table 1C . Lentigo maligna lesions were predominantly Stage 0 or I lesions, which comprised 88.6%. For superficial spreading melanomas, the most prevalent stage was Stage I (68.1%) followed by Stage II lesions (19.7%). Nodular and acral lentiginous lesions were more aggressive according to their stage at presentation. For both nodular and acral lentiginous histologies, the most common presentation was Stage II, representing 51.1% and 37.0% of these histologies, respectively. In addition, both nodular and acral lentiginous lesions presented with higher percentages of Stage III and IV disease compared with the other histologies.
Among the 4522 ocular melanomas for all years, 3846 patients (85.0%) had uveal melanomas (Table  1A) . Among these uveal melanomas, AJCC staging was recorded in 2286 patients; the percentage of patients with AJCC Stages I, II, III, and IV were 31.3%, 28.9%, 31.9%, and 7.4%, respectively. There were 216 patients with conjunctival melanomas. The remaining 460 patients with ocular melanomas were classified as "other" and comprised cornea, NOS; retina; lacrimal gland; orbit, NOS; overlapping lesion of the eye; and eye, NOS.
There is no recommended AJCC stage groupings for conjunctival melanomas, and no staging classification for mucosal melanomas. However, when information could be retrieved from the medical records, the lymph node status of mucosal melanomas was recorded. Among the 1074 mucosal melanomas for all years, lymph node status was recorded in 28.4% of cases (Table 2 ). This represented 305 cases, 40.3% of which had positive lymph nodes and 59.7% of which had negative lymph nodes. A breakdown of lymph node status by site revealed that the incidence of positive lymph nodes for head and neck, female genital tract, anal/rectal, and urinary tract melanomas was 26.6%, 23.0%, 61.0%, and 11.1%, respectively. The presence of positive lymph nodes in mucosal melanomas had a significant adverse effect on survival.
Patient Characteristics
Patient characteristics were broken down for all years with respect to cutaneous, mucosal, ocular, and unknown primary melanoma classifications in Table 3A .
Compared with other histologic groups, there was a definite trend toward a skewing of older patients diagnosed with mucosal melanomas with 49.0% of patients being age Ն70 years. As one would expect, there was a higher percentage of females (63.5%) than males diagnosed with mucosal melanomas due to lesions arising in the female genital tract. By contrast, there Table 3B . There were large differences between histologies with respect to age and race/ethnicity. A larger percentage of older patients presented with lentigo maligna lesions compared with the other histologies; 76.7% of the patients diagnosed with lentigo maligna were age Ն60 years compared with 33.5%, 46.5%, and 61.8% for superficial spreading, nodular, and acral lentiginous histologies, respectively. With regard to race/ethnicity, African Americans and Hispanics comprised 15.9% of all patients diagnosed with acral lentiginous melanomas whereas individuals of these racial/ethnic backgrounds comprised only 1.3%, 1.2%, and 1.9% of patients diagnosed with lentigo maligna, superficial spreading, or nodular melanomas, respectively. Levels of income were not substantially different between these histologic classifications.
Treatment
The vast majority (91.5%) of cutaneous melanomas were treated with surgery alone (Table 4) . Surgery alone also was the primary modality, but to a lesser extent, for managing mucous membrane melanomas (56.4%) and ocular melanomas (57.0%). A higher percentage of these noncutaneous melanoma patients also received radiation therapy, either alone (25.7% of ocular melanomas) or in combination with surgery (19.3% of mucous membrane melanomas). Approximately 58% of patients with unknown primary melanomas were treated surgically with or without radiation therapy and/or chemotherapy for management of the metastasis. However, a substantial percentage (17.7%) received no treatment in the form of surgery, radiation therapy, or chemotherapy. Although not shown in Table 4 , there were few changes across the years in treatment for the various sites. However, surgery with radiation therapy has been used with increasing frequency for treating mucous membrane melanomas (from 
Survival
Disease specific survival analyses, performed on patients diagnosed between 1985-1989, indicated that 78.8% were alive 5 years after diagnosis (Table 5A) . When stratified by anatomic site, cutaneous melanomas had the highest 5-year survival rate (80.8%), followed by ocular melanomas (74.6%). The proportion of patients with mucous membrane melanoma who survived 5 years was much lower (25.0%). Patients with unknown primary site of the melanoma also had a low survival rate, with only 29.1% alive at 5 years. Mucosal melanomas were analyzed with respect to site and lymph node status. Patients with head and neck, female genital tract, and anal/rectal mucosal melanomas had 5-year survival rates of 31.7%, 11.4%, Patients with ocular melanomas had survival broken down between uveal and conjunctival sites. The overall, 5-year survival for uveal and conjunctival melanomas was 83.5% and 75.7%, respectively, which was not significantly different. The majority of ocular melanomas were of uveal origin. Among uveal melanomas, patients with AJCC Stages I, II, III, and IV had survival rates of 83.9%, 84.9%, 64.4%, and 59.3%, respectively (Fig. 1) . All stage subgroups were significantly different from each other.
Cutaneous melanoma survival rates were disaggregated by "combined" stage when staging information was available in 13,547 patients (Fig. 2) . For Stage 0 melanomas (also known as melanomas in situ), the 5-year survival rate was 96.0%. For localized, invasive melanomas (representing Stages I and II), the survival rates were 92.5% and 74.8%, respectively. Lymph node positive Stage III patients had a survival rate of 49.0%, whereas Stage IV patients with metastatic disease had a survival rate of only 17.9% (Fig. 2) . All stage subgroups were significantly different from each other.
A breakdown of cutaneous melanoma survival according to histologic subtype is summarized in Table  5B . The 5-year survival rates for lentigo maligna, superficial spreading, nodular, and acral lentiginous a Income groupings based on the lowest (Ͻ $20,000) and highest (Ն$47,000) 10% of all cancer patients on the National Cancer Data Base data set.
melanoma were 93.2%, 91.6%, 64.6%, and 66.4%, respectively. All histologic subgroups were significantly different from each other except the nodular and acral lentiginous subgroups. One potential factor contributing to differences in survival between certain histologic subtypes most likely is due to the distribution of stages within each group. As indicated in Table 1C , both the nodular and acral lentiginous melanoma subtypes were comprised of a higher percentage of Stage II, III, and IV cases compared with the lentigo maligna and superficial spreading histologic subtypes. When accounting for stage, patients with nodular melanomas still fared significantly worse than individuals with superficial spreading melanomas for all stages of invasive disease (Table 5B ). There were no significant differences in survival for patients with superficial the 5-year survival rates for patients with low income versus high income were 30.0% and 45.4%, respectively, but the difference was not statistically significant. For cutaneous melanoma, age, gender, race, income, stage, and histology indicated significantly different survival rates within their stratifications. These six variables were entered into a Cox regression analysis as dichotomous variables (Table 5D ). Age was Ͻ60 or Ն60 years, gender was male or female, race was white or minority individuals, income was individuals in the lower 50% or the upper 50%, stage was early or advanced, and histology was nodular and acral lentiginous (with low 5-year survival rates of 64.6% and 66.4%, respectively) or lentigo maligna and superficial spreading (with high 5-year survival rates of 93.2% and 91.6%, respectively). Race was the only variable that was not significantly associated with survival. The strongest predictors were stage (with advanced disease having a 2.08 relative risk value) and histology (with the classifications demonstrating lower survival rates [nodular and acral lentiginous] having a 1.78 relative risk value). The relative risk values for the remaining variables were 1.33 for males, 1.20 for patients age Ն60 years, and 1.12 for patients in the lower 50% income bracket.
The survival of patients determined to have metastases from unknown primary sites were evaluated with respect to regional versus distant disease at presentation. Patients with regional disease (i.e., lymph node) had a 5-year survival rate of 46.3% compared with a rate of only 15.8% for patients who presented with distant (i.e., nonlymph node) sites of disease, a statistically significant difference (P Ͻ 0.0001) ( Table  5E ). The survival of individuals with unknown primary melanomas was analyzed further with respect to treatment. Treatment was grouped into surgical resection (with or without adjuvant treatment) or no treatment. For all patients with unknown primary melanomas, the 5-year survival rate for those patients undergoing surgical resection (38.8%) was significantly better than that for patients who received no treatment (19.6%). This was broken down further into individuals with regional (i.e., lymph node) or distant disease at presentation. For regional presentation, the 5-year survival rates for patients with surgical treatment versus those with no treatment were 54.5% and 26.5%, respectively (with the number of patients receiving no treatment being too small for statistical comparisons). For distant presentation, 5-year survival rates associated with surgical treatment versus no treatment were 20.3% and 15.9%, respectively, which represented a statistically significant difference.
DISCUSSION
Based on hospital registry data during a 10-year period, this report documents the relative percentages of cutaneous and noncutaneous melanomas diagnosed in Ͼ86,000 patients. To our knowledge, this represents one of the largest databases comprising patient characteristics, histology, staging, therapy, and survival for melanomas. The last NCDB study of melanoma, reported in 1994, reviewed 20,165 cases of cutaneous melanoma. 13 Prior to that, the American College of Surgeons performed a Patient Care Evaluation study of cutaneous and noncutaneous melanoma comprising 11,904 patients that was reported in 1992. 14 In the current study, cutaneous melanomas comprised 91.2% of the cases, followed by ocular (5.3%), unknown primary (2.2%), and mucosal (1.3%) melanomas. The peak age at diagnosis for cutaneous, ocular, and unknown primary site of melanomas was between ages 60 -69 years. By contrast, for mucosal melanomas, the peak age of incidence was between ages 70 -79 years. There was a predominance of white individuals diagnosed with cutaneous, ocular, and unknown primary site of melanomas, with AfricanAmerican or Hispanic individuals comprising only 5.4% and 3.4% of cases, respectively.
In discussing the results by anatomic site of origin, cutaneous melanoma patients represented the majority of individuals in the data base, totaling 77,347 cases. Among the patients diagnosed between 1985- 1989, the overall 5-year survival was 80.8%. As expected, survival was associated with stage. Stage 0 (in situ melanoma) and Stage I disease were highly curable, with 5-year survival rates of 96.0% and 92.5%, respectively. Fortunately, 62.6% of patients diagnosed with melanoma fell into these stage groups. Surgical excision was the major therapeutic modality, employed in 94.8% of patients alone or in concert with other modalities. Of the patients in this database who had information regarding the administration of biologic response modifier therapy, only 2.9% were treated with this modality. Because of the recent findings that interferon-␣ is an effective adjuvant therapy after surgery for patients with Stage III disease, it is anticipated that there will be an increase in the use of this biologic response modifier in the future. 15 Moreover, vaccine therapies have seen a resurgence of interest in the management of patients with melanoma. 16, 17 Of interest was the association between histologic subtype (i.e., lentigo maligna, superficial spreading, nodular, and acral lentiginous) and survival. Both the lentigo maligna and superficial spreading subgroups presented with a higher percentage of earlier stage disease (Stages 0 through II). By contrast, the nodular and acral lentiginous subgroups presented with a higher proportion of advanced disease (Stages III and IV), underscoring the aggressive biology of these histologic subtypes. Even when accounting for stage, the nodular histologic subtype behaved more aggressively than the lentigo maligna and superficial spreading subgroups. These observations validate the continued use of these histologic descriptions in the reporting of pathologic diagnoses of melanomas. There have been other histologic features that may account for the observed differences in this report, including ulceration, vertical growth phase, angiolymphatic invasion, mitotic activity, presence of infiltrating lymphoid cells, and evidence of regression. 18 -20 However, these features were not recorded within the hospital cancer registries from which the NCDB is drawn, and therefore could not be analyzed. Because of the NCDB's large database of cutaneous melanoma patients, the effects of different patient characteristics on survival could be evaluated. Age Ն60 years was found to be an adverse prognostic factor for both early stage and advanced stage disease. Analysis of age by increasing decades also demonstrated the same trend of decreased survival (data not shown). Deaths due to causes unrelated to melanoma were censored and only disease specific survival data were calculated. Hence, comorbid conditions associated with increasing age were unlikely to be reasons for decreased survival from cutaneous melanoma.
Gender was found to be a significant prognostic factor, with males having worse survival than females. This was true for both early stage and advanced stage patient groups. It is known that the distribution of the anatomic origin of cutaneous melanomas differs between males and females; women have a higher percentage of extremity melanomas, whereas males have a higher percentage of truncal melanomas. 21 The axial location of melanoma has been reported to be associated with a worse prognosis. 22 In the NCDB the percentage of males and females with axial melanomas (i.e., head and neck or truncal sites) was 64.8% and 39.1%, respectively. The proportion of males with cutaneous melanomas of the extremities (i.e., arm/shoulder and leg/hip) was 39.2% compared with 55.4% for females. The gender differences identified in this database also may be related to hormonal influences on the prognosis of melanoma. With respect to race/ethnicity, whites fared better than nonwhites (i.e., African Americans and Hispanics) for early stages of melanoma. There was a trend toward poorer survival in nonwhite patients who presented with advanced melanoma compared with whites; however, the numbers were too small to reach sta- tistical significance. Also interesting was the differences in survival related to income levels. There was a direct relationship between increasing income level and improved survival in patients with early stages of cutaneous melanoma. This trend also was observed for advanced stage melanoma; however, the numbers again were too small to reach statistical significance. A multifactorial analysis was performed to determine which case-mix variables (AJCC stage, histologic subtype, age, gender, race, and income) were predictive of survival for cutaneous melanoma. The factors that proved to be independent predictive factors for survival, in decreasing order, were: stage, histology, gender, age, and income. We are not aware of any report documenting income as a prognostic factor for cutaneous melanoma. In cross-tabulations, higher income levels (i.e., low, middle, and high) were associated with lower stages of disease at presentation (data not shown). Nevertheless, the multivariate analysis demonstrated income to be an independent prognostic factor in addition to stage, which indicates that the effects of income on survival are due to influences besides stage. These effects of income on melanoma survival are unknown and should be investigated further because it is a factor that potentially can be altered.
For all years, there was a total of 4522 ocular melanomas, 85.0% of which were uveal and 4.8% of which were conjunctival lesions. Surgery has been the mainstay of treatment over all years; however, there was a significant increase in the use of primary radiation therapy as the sole treatment between 1985-1989 and 1990 -1994 (from 17.0% to 30.4%).
A total of 1074 mucosal melanomas was recorded in the database. The overall, 5-year survival rate of those patients diagnosed between 1985-1989 was only 25.0%. The most prevalent site of mucosal melanomas was the head and neck region (55.4%), followed by anal/rectal melanomas (23.8%). Surgery was the main component of treatment in 80.5% of cases. The combined approach of utilizing surgery plus radiation therapy for mucosal melanomas involved 19.3% of patients compared with 1.4% for cutaneous melanomas. Approximately one-third of patients with mucosal melanomas had positive lymph nodes when lymph node status was known. The presence of positive lymph nodes was associated with a 5-year survival of 16.4% compared with 38.7% for patients with negative lymph nodes. These findings document the important prognostic effect of lymph node status in mucosal melanomas, which should be incorporated in any formal staging system established for this disease entity.
Patients with unknown primary melanomas fared poorly. The database contained information that permitted identification of whether the patients presented with regional or distant metastases. If one assumes that the predominant source of these unknown primary melanomas arose from a cutaneous site that spontaneously regressed, it is interesting to note that the 5-year survival rate of patients with regional metastasis (46.3%) was similar to the rate of survival for patients with Stage III cutaneous melanoma (49.0%). In addition, patients with distant metastases from unknown primary sites had a 5-year survival rate (15.8%) that was similar to the survival of Stage IV cutaneous melanoma (17.7%). Despite the poor prognosis of this category of patients, surgical treatment did result in a significant 5-year benefit in this subgroup of patients compared with the subgroup of patients given no treatment. Although there most likely is a selection bias in favor of patients who received surgical therapy versus those who received no treatment, several reports have observed that the surgical management of patients with lymph node disease from unknown primary melanomas fared as well as patients with known cutaneous primary sites. 23 The data in this current report appear to substantiate the potential benefit of surgical resection of patients with isolated lymph node or visceral disease from unknown primary melanomas.
In summary, patients with cutaneous melanomas fared much better than patients with noncutaneous These results were obtained using Cox regression analysis. a The cutaneous histologies with higher 5-year survival (lentigo maligna and superficial spreading, with 93.2% and 91.6% rates, respectively) were grouped together and compared with the histologies with lower 5-year survival (nodular and acral lentiginous, with 64.6% and 66.4% rates, respectively). b Not applicable because race was not significant. melanomas after treatment. Fortunately, the majority of individuals with cutaneous melanomas present at an early stage when therapy is highly successful in achieving 5-year cure rates. The mainstay of therapy for patients with melanomas of all sites has been surgical excision, except for patients with ocular melanomas, in whom a significant trend toward primary radiation therapy has been observed. Surgical resection of isolated disease due to unknown primary site of the melanomas should be instituted when medically feasible because a subgroup of those patients fare well. Hopefully, with a better understanding of the biologic and socioeconomic factors influencing melanoma treatment, the survival of patients with melanoma will improve. In this regard, adjuvant strategies utilizing biologic response modifiers after surgical resection appear promising. 
